BLOG
Life Sciences


IDMP: A Big Data Challenge for European Pharma

Written by Andrew Marr in Life Sciences on 23/05/17


At this year’s AMPLEXOR “Be The Expert 2017” event, Pharm Exec spoke to Andrew Marr about the implications of the EU’s new IDMP (Identification of Medicinal Products) regulations for the pharmaceutical industry.

Read more

Update to IDMP Iteration 1

Written by Steve Scribner in Life Sciences on 23/06/16


The ISO IDMP Task Force met in April to compile recommended changes to the content of the information model. A revised draft version was scheduled for vote in the meeting on May 12. A revised timeline was also on schedule to be discussed. We will publish an update in the next blog.

Read more

Regulatory transformation: the time is now

Written by Siniša Belina in Life Sciences on 21/06/16


Regulatory compliance has always been a double-edged sword for life sciences. It is an essential and central focus for investment because public safety, consumer confidence and sales depend on it. Yet this preoccupation with rules and risk can also be a barrier to innovation, because any deviation from the status quo increases the chance of non-compliance.

Read more

Reinventing data management, with R&D at the centre

Written by Steve Scribner in Life Sciences on 30/03/16


Every business, and often every department, has its own way of doing things. In the life sciences industry this is true of the way companies and individual business functions record and manage information about drugs, making it difficult to gain a clear line of sight across a product’s lifecycle and its performance in the market. This has implications for the business as well as public safety.

Read more